Compliance, PatientCOCOONNCT06017063
Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields
A study testing Psychological intervention in people with Compliance, Patient and Glioblastoma, run by University Hospital Tuebingen.
Trial summary
The aim is to improve patients' compliance to TTFields therapy by a psychological video intervention in a multi-center, randomized controlled trial. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Compliance, Patient, Glioblastoma, Astrocytoma, Grade IV
- What is being tested?
- Psychological intervention
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 275 participants
- Where
- No sites listed yet
- Study dates
- Oct 2023to Sep 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Ability to understand and give an informed consent, capacity to consent
- Given informed consent
- ≥ 18 years of age
- Patients with newly diagnosed glioblastoma
- Patients with IDH-mutant Astrocytoma, CNS WHO-Grade 4, newly diagnosed (by biopsy or incomplete tumor resection)
- Patients eligible for radiochemotherapy with temozolomide and 60 Gy
Show all 10Show fewer
- Patients before radiochemotherapy phase or within the first 2 weeks
- Prescription of TTFields according clinical routine (including but not exclusive to)
- Access to a computer and internet
- Absence of medical reasons precluding participation in a supportive intervention
Who cannot join
- Ability to understand and give an informed consent, capacity to consent
- Given informed consent
- ≥ 18 years of age
- Being a family caregiver of a patient with newly diagnosed glioblastoma
- Access to a computer and internet
- Absence of medical reasons precluding participation in a supportive intervention
Trial locations and contacts
No sites are listed yet.
About this study
The aim is to improve patients' compliance to TTFields therapy by a psychological video intervention in a multi-center, randomized controlled trial.
Read the detailed description
Patients diagnosed with a glioblastoma and their family caregivers are mainly impaired by the poor prognosis and the high symptom burden. Caregivers report impaired health-related quality of life (HRQOL) and high distress. They even may experience significantly higher levels of anxiety and depression than patients themselves . Furthermore, Boele et al. showed that the overall survival in glioblastoma patients is associated with family caregivers' mastery.
In newly diagnosed glioblastoma, the EF-14 RCT demonstrated significantly prolonged survival in patients treated with TTFields compared to controls, with a median overall survival (OS) of 20.9 vs 16.0 months.
Several studies showed an important association of the daily compliance rate with OS and progression-free survival (PFS). Family caregivers' support might be associated to the patients' compliance and adequate support is required. However, so far rare supportive programs for patients and their caregivers have been established. It has been shown that delivery of supportive care via telehealth is feasible, however studies examining the effectiveness, adoption and maintenance of telehealth interventions in glioblastoma patients and family caregivers are still lacking. The aim is to improve patients' compliance to TTFields therapy by a psychological video intervention.
It is a multi-center, randomized controlled trial.
Main inclusion criteria are:
- Diagnosis of a GBM/being a GBM patient's caregiver
- Patients eligible for radiochemotherapy with TMZ and 60Gy
- Tumorboard recommendation for TTFields therapy
- Access to a computer and internet
- Absence of medical reasons precluding participation in a supportive intervention
The experimental intervention is:
Delivery of supportive care via telehealth intervention (including a brief psychological intervention and information/educational support regarding the disease, therapy and self-help options) in family caregivers and patients
The intervention encompasses six interventions (video call) for patients and caregivers.
The six sessions will be conducted by the psychologists of the coordinating center to allow homogeneous and sound implementation of the BPI. All psychologists are certified psychooncologists.
The first part of the sessions is scheduled immediately after start of radiochemotherapy (+ 2 weeks) in order to guide patients and caregivers in this important phase after first diagnose.
- First session/week 1 (+ 2 weeks) after start of radiochemotherapy: Engage and motivate patients and caregivers to participate and to develop open communication (60-90min), followed by a follow up phone call a few days later.
- Second session/week 2 (+ 2 weeks) after start of radiochemotherapy: Review of the last session and follow-up phone. Education on the techniques for optimistic attitude (including positive self-talk, positive thinking, and speaking positive). Discussion about necessity of setting achievable short-term goals in treatment process. Homework: "Write at least 3 achievable short-term goals" (45 min), followed by a follow up phone call a few days later.
The second part of the sessions is scheduled after completion of radiochemotherapy phase (+ 2 weeks) with focus in the adjuvant temozolomide therapy and TTFields therapy.
- Third session/week 7 (+ 2 weeks) after completed radiochemotherapy: Review of the last session, discussion over the phone, and homework. Providing information or advice about treatment, the TTFields therapy and medication.
- Responding to hopelessness (focusing on positive details of the clinical course, the progress which patients made since surgery, but also sharing fears, and negative thoughts). Sharing community resources (websites, hospitals, and counseling centers).
- Importance of TTFields therapy and association of daily compliance rate with prognosis, FAQ list, recommendations and practical aspects
- Homework: "Provide a list of supportive resources in your community" "Provide a list of questions to the health care professionals" (45-60min), followed by a follow up phone call a few days later.
- Fourth session/week 8 (+ 2 weeks) after completed radiochemotherapy:
- Education on the techniques for stress management (including physical activity, social contact/relationship, spending time in activity and nature (60-90 minutes) and healthy lifestyle behaviors.
- Questions regarding TTFields and chemotherapy
- Homework: "List the useful strategies to manage your stress during the treatment process of your partner", "Apply stress management techniques". (45-60min), followed by a follow up phone call a few days later.
- Fifth session/week 9 (+ 2 weeks) after completed radiochemotherapy:
- First assessment after start of TTFields therapy, evaluation of practical questions and well-being
- Education of self-care strategies (including eating well-balanced meals, permission to feel bad-schedule it in your day, permission to feel good, put off major life decisions (if it is possible), take breaks from periods of isolation, exercise - even a little bit, and let yourself cry (45-60 min).
- Sixth session/week 10 (+ 2 weeks) after completed radiochemotherapy: Feedback regarding the sessions before and planning of implementation of the learned strategies for the upcoming months. Homework: "List the strategies personally useful and what personally motivates you, learned in the last weeks"
The control condition is: Standard of care with standard access to psychosocial support in certified Neuro-Oncological Centers
Primary Outcome:
Compliance to TTFields compared in intervention and control group
Secondary Outcomes:
- Patients' health-related quality of Life (HRQoL), symptom burden, self-efficacy, anxiety, depression and its association to the intervention.
- Patient- and family caregiver-reported acceptance of intervention, patients´ acceptance of TTFields
- Adverse event of special interest: Skin irritation
- Patients' and family caregivers emotional and physical well-being,
- Correlation between endpoints to investigate dependencies of underlying concepts.
- Analysis of health utilization measures.
Optional Outcomes:
On a voluntary basis the following biosamples will be acquired for assessment of stress level and immunogenic response
- hair probes
- blood
- Conditions
- Compliance, Patient, Glioblastoma, Astrocytoma, Grade IV
- Being tested
- Psychological intervention
- Keywords
- psychosocial support
- Medical subject headings
- Patient Compliance, Glioblastoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Psychological interventionOther
The intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual.
| Study group | Role | What they receive |
|---|---|---|
| Intervention arm | Experimental | Patients and caregivers will participate in support program encompassing six video interventions with the BPI. Both participate in the intervention at the same time and together. The intervention starts within two weeks after start of the radiochemotherapy phase, see also figure 2. Patients and caregivers will receive an invitation link to the Vidyo sessions and can log in together to participate in the sessions. Receives: Other: Psychological intervention |
| Control arm | No intervention | Patients and caregivers randomized to the control group, they will not receive the 6-week intervention by the psycho-oncologist. However, they are still entitled to guideline-based psycho-oncology counseling according to the guideline and local standard if they wish. Subsequently, they will be supported regarding coping with the disease, how to improve their mood, or which strategies are available in dealing with the disease. This conversation will last 30-60 minutes. |
What is being measured
The primary outcome is the main question the study is designed to answer.
EFFICACY of intervention
Compliance to TTFields compared in intervention and control group.Compliance will be measured by the duration of the TTFields application in each patient
Measured: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)
Secondary outcomes (3)
TOLERABILITY of psychooncological intervention
Patient- and caregiver-reported acceptance of intervention as measured by number of patient and cargiver dyads who completed the 6th session of the psychooncological intervention
Measured: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)
Safety of TTFields
Adverse event of special interest: Skin irritation in patients under TTFields therapy
Measured: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)
Incidence of burdened caregivers
Caregiver emotional and physical well-being, patient emotional and physical well-being
Measured: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Aug 2023
- Study startOct 2023 (estimated)
- Primary completionApr 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Compliance, PatientStudies of the same condition, open and under way.
- More trials run by University Hospital TuebingenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- randomized controlled trial
- Masking
- None (open label)
- Enrolment
- 275 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital Tuebingen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06017063
- Sponsor's protocol ID
- 345/2023BO1
- Acronym
- COCOON
- Status last verified
- Jul 2023
- First submitted
- 12 Jul 2023
- Last updated
- 30 Aug 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 30 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields
- ClinicalTrials.gov ID
- NCT06017063
- Acronym / sponsor ID
- COCOON / 345/2023BO1
- Conditions
- Compliance, Patient, Glioblastoma, Astrocytoma, Grade IV
- Keywords
- psychosocial support
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 275 participants (estimated)
- Lead sponsor
- University Hospital TuebingenUniversity, hospital or other
- Study start
- Oct 2023 (estimated)
- Primary completion
- Apr 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 30 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim is to improve patients' compliance to TTFields therapy by a psychological video intervention in a multi-center, randomized controlled trial.
Detailed description
Patients diagnosed with a glioblastoma and their family caregivers are mainly impaired by the poor prognosis and the high symptom burden. Caregivers report impaired health-related quality of life (HRQOL) and high distress. They even may experience significantly higher levels of anxiety and depression than patients themselves . Furthermore, Boele et al. showed that the overall survival in glioblastoma patients is associated with family caregivers' mastery.
In newly diagnosed glioblastoma, the EF-14 RCT demonstrated significantly prolonged survival in patients treated with TTFields compared to controls, with a median overall survival (OS) of 20.9 vs 16.0 months.
Several studies showed an important association of the daily compliance rate with OS and progression-free survival (PFS). Family caregivers' support might be associated to the patients' compliance and adequate support is required. However, so far rare supportive programs for patients and their caregivers have been established. It has been shown that delivery of supportive care via telehealth is feasible, however studies examining the effectiveness, adoption and maintenance of telehealth interventions in glioblastoma patients and family caregivers are still lacking. The aim is to improve patients' compliance to TTFields therapy by a psychological video intervention.
It is a multi-center, randomized controlled trial.
Main inclusion criteria are:
- Diagnosis of a GBM/being a GBM patient's caregiver
- Patients eligible for radiochemotherapy with TMZ and 60Gy
- Tumorboard recommendation for TTFields therapy
- Access to a computer and internet
- Absence of medical reasons precluding participation in a supportive intervention
The experimental intervention is:
Delivery of supportive care via telehealth intervention (including a brief psychological intervention and information/educational support regarding the disease, therapy and self-help options) in family caregivers and patients
The intervention encompasses six interventions (video call) for patients and caregivers.
The six sessions will be conducted by the psychologists of the coordinating center to allow homogeneous and sound implementation of the BPI. All psychologists are certified psychooncologists.
The first part of the sessions is scheduled immediately after start of radiochemotherapy (+ 2 weeks) in order to guide patients and caregivers in this important phase after first diagnose.
- First session/week 1 (+ 2 weeks) after start of radiochemotherapy: Engage and motivate patients and caregivers to participate and to develop open communication (60-90min), followed by a follow up phone call a few days later.
- Second session/week 2 (+ 2 weeks) after start of radiochemotherapy: Review of the last session and follow-up phone. Education on the techniques for optimistic attitude (including positive self-talk, positive thinking, and speaking positive). Discussion about necessity of setting achievable short-term goals in treatment process. Homework: "Write at least 3 achievable short-term goals" (45 min), followed by a follow up phone call a few days later.
The second part of the sessions is scheduled after completion of radiochemotherapy phase (+ 2 weeks) with focus in the adjuvant temozolomide therapy and TTFields therapy.
- Third session/week 7 (+ 2 weeks) after completed radiochemotherapy: Review of the last session, discussion over the phone, and homework. Providing information or advice about treatment, the TTFields therapy and medication.
- Responding to hopelessness (focusing on positive details of the clinical course, the progress which patients made since surgery, but also sharing fears, and negative thoughts). Sharing community resources (websites, hospitals, and counseling centers).
- Importance of TTFields therapy and association of daily compliance rate with prognosis, FAQ list, recommendations and practical aspects
- Homework: "Provide a list of supportive resources in your community" "Provide a list of questions to the health care professionals" (45-60min), followed by a follow up phone call a few days later.
- Fourth session/week 8 (+ 2 weeks) after completed radiochemotherapy:
- Education on the techniques for stress management (including physical activity, social contact/relationship, spending time in activity and nature (60-90 minutes) and healthy lifestyle behaviors.
- Questions regarding TTFields and chemotherapy
- Homework: "List the useful strategies to manage your stress during the treatment process of your partner", "Apply stress management techniques". (45-60min), followed by a follow up phone call a few days later.
- Fifth session/week 9 (+ 2 weeks) after completed radiochemotherapy:
- First assessment after start of TTFields therapy, evaluation of practical questions and well-being
- Education of self-care strategies (including eating well-balanced meals, permission to feel bad-schedule it in your day, permission to feel good, put off major life decisions (if it is possible), take breaks from periods of isolation, exercise - even a little bit, and let yourself cry (45-60 min).
- Sixth session/week 10 (+ 2 weeks) after completed radiochemotherapy: Feedback regarding the sessions before and planning of implementation of the learned strategies for the upcoming months. Homework: "List the strategies personally useful and what personally motivates you, learned in the last weeks"
The control condition is: Standard of care with standard access to psychosocial support in certified Neuro-Oncological Centers
Primary Outcome:
Compliance to TTFields compared in intervention and control group
Secondary Outcomes:
- Patients' health-related quality of Life (HRQoL), symptom burden, self-efficacy, anxiety, depression and its association to the intervention.
- Patient- and family caregiver-reported acceptance of intervention, patients´ acceptance of TTFields
- Adverse event of special interest: Skin irritation
- Patients' and family caregivers emotional and physical well-being,
- Correlation between endpoints to investigate dependencies of underlying concepts.
- Analysis of health utilization measures.
Optional Outcomes:
On a voluntary basis the following biosamples will be acquired for assessment of stress level and immunogenic response
- hair probes
- blood
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| Intervention arm | Experimental | Other: Psychological interventionPatients and caregivers will participate in support program encompassing six video interventions with the BPI. Both participate in the intervention at the same time and together. The intervention starts within two weeks after start of the radiochemotherapy phase, see also figure 2. Patients and caregivers will receive an invitation link to the Vidyo sessions and can log in together to participate in the sessions. |
| Control arm | No intervention | –Patients and caregivers randomized to the control group, they will not receive the 6-week intervention by the psycho-oncologist. However, they are still entitled to guideline-based psycho-oncology counseling according to the guideline and local standard if they wish. Subsequently, they will be supported regarding coping with the disease, how to improve their mood, or which strategies are available in dealing with the disease. This conversation will last 30-60 minutes. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Ability to understand and give an informed consent, capacity to consent
- Given informed consent
- ≥ 18 years of age
- Patients with newly diagnosed glioblastoma
- Patients with IDH-mutant Astrocytoma, CNS WHO-Grade 4, newly diagnosed (by biopsy or incomplete tumor resection)
Key exclusion criteria (6 listed)
- Ability to understand and give an informed consent, capacity to consent
- Given informed consent
- ≥ 18 years of age
- Being a family caregiver of a patient with newly diagnosed glioblastoma
- Access to a computer and internet
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Psychological interventionThe intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual. | Other | Intervention arm |
Primary outcome
EFFICACY of intervention
Time frame: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)
Compliance to TTFields compared in intervention and control group.Compliance will be measured by the duration of the TTFields application in each patient
3 secondary outcomes
TOLERABILITY of psychooncological intervention
Time frame: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)
Safety of TTFields
Time frame: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)
Incidence of burdened caregivers
Time frame: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Aug 2023.
- Individual participant dataSharing planned: Yes
Related trials for Compliance, Patient
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Not yet recruiting
Testing a Smartphone App to Support a Mediterranean Diet and Strength Exercise
Treatment Adherence and Compliance, Resistance Exercise
Recruiting
Hybrid mHealth and Telerehabilitation vs Conventional Physiotherapy for Subacromial Pain Syndrome
Subacromial Pain Syndrome
Not yet recruiting
Use and Acceptability of an AI-Assisted Health Application for Individuals Living With a Chronic Condition
Hypertension, Diabetes Mellitus, Type 2
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
A study testing Psychological intervention in people with Compliance, Patient and Glioblastoma, run by University Hospital Tuebingen.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 30 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Mirjam Renovanz, MD (0049 7071 29 61903, mirjam.renovanz@med.uni-tuebingen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
EFFICACY of intervention (time frame: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Aug 2023.